ARMISTICE CAPITAL, LLC
Q3 2023 13F-HR Holdings
Net value change ($000)
-382,490
(-5.5%)
New positions
82
Sold out positions
46
Turnover %
20.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMVT | 39,767 | NEW |
| BUD | 38,876 | NEW |
| IRWD | 33,281 | NEW |
| CRL | 30,573 | NEW |
| CL | 22,107 | 47.7% |
| ARGX | 20,380 | 26.1% |
| EL | 20,209 | NEW |
| THS | 19,173 | NEW |
| SN | 15,160 | NEW |
| REKR | 14,562 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Mirati Therapeutics, Inc. | -84,305 | -58.7% |
| PFE | -76,881 | -100.0% |
| JNJ | -55,210 | -72.5% |
| INCY | -50,706 | -45.9% |
| TVTX | -47,382 | -41.4% |
| PG | -31,865 | -100.0% |
| ENR | -31,229 | -100.0% |
| REGN | -27,379 | -30.7% |
| ENTA | -20,113 | -46.2% |
| SPECTRUM PHARMACEUTICALS INC | -19,200 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
3,164,664
(48.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|